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Background: Diastolic dysfunction is a key factor in the development and pathology of cardiac dysfunction in
diabetes, however the exact underlying mechanism remains unknown, especially in humans. We aimed to measure
contraction, relaxation, expression of calcium-handling proteins and fibrosis in myocardium of diabetic patients with
preserved systolic function.
Methods: Right atrial appendages from patients with type 2 diabetes mellitus (DM, n = 20) and non-diabetic patients
(non-DM, n = 36), all with preserved ejection fraction and undergoing coronary artery bypass grafting (CABG), were
collected. From appendages, small cardiac muscles, trabeculae, were isolated to measure basal and β-adrenergic
stimulated myocardial function. Expression levels of calcium-handling proteins, sarcoplasmic reticulum Ca2+
ATPase (SERCA2a) and phospholamban (PLB), and of β1-adrenoreceptors were determined in tissue samples by
Western blot. Collagen deposition was determined by picro-sirius red staining.
Results: In trabeculae from diabetic samples, contractile function was preserved, but relaxation was prolonged
(Tau: 74 ± 13 ms vs. 93 ± 16 ms, non-DM vs. DM, p = 0.03). The expression of SERCA2a was increased in diabetic
myocardial tissue (0.75 ± 0.09 vs. 1.23 ± 0.15, non-DM vs. DM, p = 0.007), whereas its endogenous inhibitor PLB
was reduced (2.21 ± 0.45 vs. 0.42 ± 0.11, non-DM vs. DM, p = 0.01). Collagen deposition was increased in diabetic
samples. Moreover, trabeculae from diabetic patients were unresponsive to β-adrenergic stimulation, despite no
change in β1-adrenoreceptor expression levels.
Conclusions: Human type 2 diabetic atrial myocardium showed increased fibrosis without systolic dysfunction
but with impaired relaxation, especially during β-adrenergic challenge. Interestingly, changes in calcium-handling
protein expression suggests accelerated active calcium re-uptake, thus improved relaxation, indicating a compensatory
calcium-handling mechanism in diabetes in an attempt to maintain diastolic function at rest despite impaired
relaxation in the diabetic fibrotic atrial myocardium. Our study addresses important aspects of the underlying
mechanisms of diabetes-associated diastolic dysfunction, which is crucial to developing new therapeutic
treatments.
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Impaired cardiac function during diastole is one of the
early manifestations of cardiac dysfunction in type 2
diabetes [1], and it makes type 2 diabetic patients prone to
developing clinical features of heart failure, with both pre-
served and reduced ejection fraction (EF) [2,3]. Diastolic
function deteriorates progressively over time [4], but the
exact mechanisms underlying this clinically important in-
creased stiffness and/or impaired relaxation, especially in
diabetes, remain unclear. In contrast to systolic dysfunc-
tion, treatments for diastolic dysfunction are limited,
which is likely due to this lack of knowledge regarding the
pathophysiology of diastolic dysfunction [5].
The diastolic properties of the heart are determined by
factors influencing both the passive compliance and the
active processes of myocardial relaxation [6]. Thus far,
studies using animals with type 1 diabetes [7] and dia-
betic patients with reduced EF [8] have found increased
collagen deposition, which stiffens the extracellular myo-
cardial matrix. More recently, the slow/incomplete re-
moval of Ca2+ from the cytosol during the diastolic
period, predominantly governed by the activity of the
important sarcoplasmic reticulum Ca2+ ATPase (SER-
CA2a) under direct control of its endogenous inhibitor
phospholamban (PLB) [9], has been shown to contribute
to the impaired myocardial relaxation in early diastolic
dysfunction [10]. However, the underlying changes in
these important calcium-handling proteins are yet to be
examined in human diabetic myocardium with preserved
EF. Moreover, as impaired diastolic function limits
cardiac performance during exercise [11] and leads to an
intolerance to tachycardia [12], it is also crucial to deter-
mine how relaxation is challenged by β-adrenergic
stimulation, one of the most important extrinsic physio-
logical stimulus of the myocardium.
Therefore we aimed to assess the impact of diabetes
on the diastolic function of the atrial myocardium from
patients with preserved EF and determine alterations in
the calcium-handling proteins specifically linked to myo-
cardial relaxation. To this end we combined active force
and relaxation measurements in isolated right atrial
cardiac muscles from non-diabetic and diabetic patients
with preserved EF and coronary artery disease (CAD),
undergoing coronary artery bypass graft (CABG) sur-
gery. Expression levels of calcium-handling proteins and
β1-adrenoreceptors were determined via protein analysis
and atrial myocardial fibrosis by measuring collagen
deposition.
Our study shows for the first time that in human atrial
myocardium from diabetic patients with preserved EF
and CAD, the force generation is preserved, whereas the
relaxation is impaired, and the right atrial cardiac mus-
cles were unresponsive to β-adrenergic stimulation. The
impairment in relaxation is associated with an unexpectedincrease in SERCA2a/PLB protein ratio in the diabetic
myocardium suggesting accelerated relaxation. This may
indicate a compensatory mechanism in an attempt to




The study was approved by the local Human Ethics
Committee (Approval number: LRS12-01-001) and in-
formed consent was obtained. Human right atrial
appendages (RAAs) were acquired from patients with
type 2 diabetes mellitus (DM, n = 20) and non-diabetic
patients (non-DM, n = 36) with CAD who underwent
CABG surgery. Non-diabetic patients were classified as
having a fasting plasma glucose ≤ 6 mmol/L or an HbA1c
score ≤ 6.5% (48 mmol/mol). DM patients were selected
based on their clinical diagnosis of type 2 diabetes with
duration of more than 1 year. CAD was of such severity
as to meet the indications for CABG, which in the
majority of cases was triple vessel or high-grade double
vessel disease (number of grafts per patient 3.7 ± 0.2 vs.
3.5 ± 0.3, non-DM vs. DM, p = 0.68). Patients requiring
emergency CABG, patients with on-going myocardial
ischemia prior to CABG and those undergoing concomi-
tant cardiac surgical procedures in addition to CABG
were excluded.
Echocardiography
All patients had a clinically indicated pre-operative
transthoracic echocardiogram, using a Vivid S6, 7, or E9
ultrasound system (GE Vingmed Ultrasound, Horten,
Norway). Images were obtained by professional echoso-
nographers, and reviewed offline by a European Associ-
ation of Cardiovascular Imaging accredited cardiologist.
Left ventricular (LV) and left atrial (LA) chamber vol-
umes were derived from a biplane method of discs using
the apical 4-chamber and 2-chamber views [13]. Cardiac
output measurements were calculated applying the heart
rate recorded during the apical 4-chamber view. Ejection
fraction (EF) was graded according to the European
Association of Echocardiography/American Society of
Echocardiography recommendations as preserved (> 50%)
[14]. LV mass was calculated according Devereux et al.
[15], whereas LV volume/mass ratio was calculated at
end-systole (LVESV/LV mass) [16].
Tissue acquisition and preservation
In all patients, RAAs were removed under normother-
mic conditions before cross clamping for cardiopulmo-
nary bypass. Immediately after removal, all specimens
were placed in a sealed vial containing a modified, low
Ca2+ (0.5 mM) Krebs-Henseleit buffer ((mM): 118.5
NaCl, 4.5 KCl, 1.4 CaCl2, 0.3 NaH2PO4, 1.0 MgCl26H2O,
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monoxime (BDM) previously well oxygenated with
carbogen (95%O2–5%CO2). Within 5–10 minutes after
removal, the appendages were either dissected into
several pieces, flash-frozen and stored at 80°C or fixed
in 4% (v/v) formaldehyde solution and stored at −20°C.
In a subset of the study, half of the RAA tissue was used
immediately to conduct the functional force measurements.
Functional force measurements
From myocardial samples, tiny cardiac muscles (trabecu-
lae) were freshly dissected, transferred to an experimen-
tal bath and attached between a force transducer and a
micromanipulator. The basal and length dependency of
force development were measured in the isolated tra-
beculae, as previously described [17]. The muscles were
constantly superfused with a modified oxygenated Krebs–
Henseleit solution, as indicated above but without BDM
and at 1.4 mM Ca2+, kept at 40°C and continuously stimu-
lated at 60 bpm (1 Hz). After mounting, the preparations
were stimulated for 1 h to allow equilibration. To impose
similar stretch levels the muscles in both groups were
stretched to the length (Lmax) at which isometric devel-
oped force was maximal. After determination of basal
force developed (Fdev), length dependency was tested by
changing muscle length from 80% to 100% Lmax with
5% incrementing steps. Hereafter the response to β-
adrenoceptor stimulation on force development was
tested with incrementing doses of dobutamine (10−7 to
10−5 M) given at 6 minutes interval.
Tissue lysate preparation and protein analysis
Total myocardial sample lysates were prepared by man-
ual grinding and followed by suspension in 1.5-fold (w/
v) sodium dodecyl sulphate (SDS) lysis buffer (3% (w/v)
SDS, 50 mM Tris–HCl (pH 7.5) and protease inhibitor
mix composed of 1 mM benzamidine, 2 μg/mL leupeptin,
2 μg/mL pepstatin A, 2 μg/mL aprotinin and 0.5 mM
phenylmethylsulfonyl fluoride). The homogenate was
incubated on ice for 1 hour, at room temperature for
45 minutes and then centrifuged at 21,000 g for 30 mi-
nutes at 4°C where after supernatant was collected.
Protein concentrations were determined using the DC
protein determination kit (BioRAD) according to man-
ufacturer’s protocol and samples volumes were ad-
justed for loading. Unless otherwise noted samples
were further solubilized in 2× Laemmli sample buffer
(65.8 mM Tris–HCl, pH 6.8, 2.1% SDS, 26.3% (w/v)
glycerol, 0.01% bromophenol blue) containing 5% β-
mercaptoethanol (v/v). Ryanodine receptor (RyR2), SER-
CA2a, PLB and β1-adrenoreceptor were detected from 75,
60, 50 or 25 μg of lysate, respectively, and glyceraldehyde
3-phosphate dehydrogenase (GAPDH) or β-actin was also
identified in each loading condition. Following transferonto nitrocellulose the membranes were blocked for
1 hour with phosphate buffered saline (PBS, pH 7.4), con-
taining 0.5% Tween 20 and 5% (w/v) skimmed milk. For
β1-adrenoceptor and β-actin proteins were transferred
onto Polyvinylidene fluoride (PVDF) membranes, blocked
for 1 hour with Tris buffered saline (TBS, pH 7.4). The
blots were probed with specific antibodies against RyR2,
SERCA2a, PLB, GAPDH (Badrilla Ltd), β1-adrenorecep-
tor (Novus Biologicals) or β-actin (Sapphire Bioscience Pty.
Ltd) with corresponding peroxidase conjugated secondary
antibodies (Sapphire Bioscience Pty.Ltd). All proteins were
detected using an enhanced chemiluminescence kit. Pro-
tein band densities were normalized to GAPDH or β-actin
as an internal control and are expressed as protein to
GAPDH or β-actin ratio. For β1–adrenoceptor (AR) blots,
β-actin was used as an internal control because GADP
was to close to the β1-AR bands to be separated accur-
ately. Although some studies suggested an impact of dia-
betes on the gene expression of GAPDH [18], others [19]
and ours did not observe any changes in protein expres-
sion of GAPDH or of β-actin (both p > 0.05) between
non-DM and DM samples.
Fibrosis determination
Formalin fixed, optical cutting temperature embedded
myocardial samples tissue sections of 8 μm thickness
were washed with distilled water and PBS, and subse-
quently exposed to a picro-sirius red solution (0.001%
(w/v) sirius red in saturated aqueous picric acid) for
1 hour. Tissue sections were then washed in acidified
H2O (0.5% (v/v) acetic acid in H2O) for 10 minutes.
Slices were dehydrogenated in an ascending ethanol
sequence (85%, 95% and 100% (v/v) in H2O) and washed
in xylene. Finally, slices were embedded in a distrene-
plasticiser-xylene mounting medium. Images obtained
by light microscopy were digitized and analyzed using
ImageJ v1.46 software to quantify the percentage of
collagen content (fibrosis), as previously described [20].
Briefly, the number of red pixels above a set threshold
(similar for all images) was calculated from the total
pixel area of interest. The area of cardiomyocytes and
collagen, excluding the lumen (i.e. empty spaces), deter-
mined the total area of interest. The mean percentage of
collagen deposition from 21 randomly selected images
was calculated to represent the level of collagen of one
RAA.
Statistical Analysis
Differences among groups were compared either using
a t-test, chi-square or a two-way ANOVA followed by
a Bonferroni post-hoc test as indicated in the legends
of the tables and Figures. A p-value of < 0.05 was
considered statistically significant. Data are expressed
as mean ± SEM.
Table 1 Patient characteristics
Clinical characteristics Non-DM (n = 36) DM (n = 20) P value
Age (years) 67 ± 1 68 ± 2 0.58
Gender (male/female) 28/8 14/6 0.52
BMI (kg/m2) 28.2 ± 0.9 33.8 ± 1.6 0.0015*
Blood glucose (mmol/L) 5.9 ± 0.3 10.0 ± 1.0 <0.0001*





Diabetes duration (years) - 11.6 ± 2.7
Diagnosed Hypertension 29/36 18/20 0.47
Echocardiography
Systolic BP (mmHg) 129 ± 3 133 ± 4 0.49
Diastolic BP (mmHg) 73 ± 2 70 ± 2 0.40
Heart rate (bpm) 64 ± 1 69 ± 2 0.07
LVEDV (mL) 104 ± 3 95 ± 5 0.20
LVESV (mL) 43 ± 2 39 ± 4 0.43
SV (mL) 61 ± 2 56 ± 3 0.17
Cardiac Output (L/min) 3.8 ± 0.1 4.0 ± 0.1 0.47
Ejection Fraction (%) 60 ± 1 60 ± 2 0.86
IVSd (cm) 1.14 ± 0.04 1.26 ± 0.06 0.08
LVPWd (cm) 1.05 ± 0.03 1.15 ± 0.06 0.15
LVIDd (cm) 4.76 ± 0.09 4.72 ± 0.15 0.81
LVIDs (cm) 3.04 ± 0.10 3.04 ± 0.14 0.99
LV mass (g) 193 ± 11 217 ± 18 0.22
LV volume/mass (ml/g) 0.22 ± 0.03 0.19 ± 0.03 0.23
E (m/sec) 0.68 ± 0.03 0.79 ± 0.05 0.05
A (m/sec) 0.69 ± 0.03 0.80 ± 0.05 0.08
E/A 1.05 ± 0.08 0.99 ± 0.08 0.63
e' (m/sec) 0.069 ± 0.003 0.067 ± 0.004 0.63
E/e' 10.5 ± 0.8 12.6 ± 1.1 0.01*
Decel (msec) 226 ± 7 259 ± 13 0.02*
LA-2D (cm) 4.0 ± 0.1 4.1 ± 0.2 0.55
Medication
Statins 35/36 (97%) 20/20 (100%) 0.45
Beta-blockers 31/36 (86%) 15/20 (75%) 0.30
ACE inhibitors/AT blockers 19/36 (53%) 19/20 (95%) 0.0012#
Calcium Channel blocker 7/36 (19%) 8/20 (40%) 0.10
Metformin 0/36 (0%) 14/20 (70%)
Insulin 0/36 (0%) 6/20 (30%)
BMI – body mass index; BP – blood pressure; HbA1c – glycated haemoglobin;
LVEDV: left ventricular end diastolic volume; LVESV: left ventricular end systolic
volume; SV: stroke volume; IVSd: interventricular septal diameter diastole;
LVPWd: left ventricular posterior wall thickness end-diastole; LVIDd: left
ventricular internal diameter diastole; LVIDs: left ventricular internal diameter
systole; LV volume/mass: LVESV / LV mass; E: early ventricular filling velocity; e’:
early ventricular myocardium relaxation velocity; A: late ventricular filling velocity;
Decel: early ventricular deceleration time; LA-2D: left atrial 2-dimensional
diameter. Data are mean ± SEM; For values: * = p< 0.05 vs. non-diabetic, unpaired
t-test; For ratios: # = p< 0.05 vs. non-diabetic, Chi-square test.
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Clinical characteristics
Diabetes was evident from the high fasting levels of
glycated hemoglobin (HbA1c) (58 ± 4 mmol/mol in DM
group, normal below 48 mmol/mol) and fasting plasma
blood glucose levels (10.0 ± 1.0 mmol/L in DM group,
normal below 6.1 mmol/L) (Table 1). All patients had
preserved EF (> 50%), and no differences in blood pres-
sures, heart rate, cardiac dimensions, LV mass or LV
volume/mass ratio were observed between both groups,
suggesting normal systolic function and no additional
structural remodeling in DM patients with CAD com-
pared to the non-DM patients with CAD. Although
almost all patients were previously diagnosed with
hypertension, the incidence was not different between
non-DM and DM patients, whereas non-hypertensive
blood pressure values indicate the effectiveness of the
blood pressure lowering treatment. In contrast, dia-
stolic function was reduced in DM compared to non-
DM patients (Table 1) as indicated by a significantly
slower early filling time (prolonged early deceleration
time, p < 0.05), by a significantly elevated marker of
ventricular filling pressures (increased E/e’, p < 0.05)
and by the tendency to slower early and late filling
velocity (increased E and A, p = 0.05 and p = 0.08,
respectively).
Human atrial myocardial function
The dimensions of right atrial trabeculae dissected were
not different between groups (Table 2) and were well
below the range that oxygen diffusion impact the core of
the trabeculae [21]. Under resting conditions (1 Hz,
Lmax), the contractile parameters (Fdev, +dF/dtmax) were
not different between muscles from non-DM and DM
patients, however the relaxation parameters, minimum
rate of relaxation (−dF/dtmin), 50% relaxation time (RT50%)
and time constant of relaxation (Tau), were significantly
prolonged in DM group (Table 2). Figure 1 shows that the
force-length relationship, one of the most important intrin-
sic functional regulatory mechanisms of the heart (the
Frank-Starling mechanism), was preserved in both cohorts,
as indicated by increasing contractile parameters (Fdev
and + dF/dtmax) with incrementing length (Figure 1A and B).
In contrast to the lack of difference in contractile
parameters between cardiac muscle from non-DM and DM
patients, the diabetic muscles showed a significant decrease
in -dF/dtmax (Figure 1C) and a prolonged Tau (Figure 1D)
at all lengths indicating impaired relaxation. Together these
data indicate preserved contraction but impaired relaxation
in cardiac muscles from DM patients with preserved EF.
Calcium-handling proteins expression levels
To evaluate whether changes in expression of calcium-
handling proteins might contribute to the observed
Table 2 Basal characteristics and functional parameters of
human cardiac muscle
Muscle characteristics Non-DM (n = 8) DM (n = 6) P value
CSA (mm2) 0.046 ± 0.036 0.051 ± 0.043 0.84
Lmax (mm) 1.73 ± 0.58 1.34 ± 0.15 0.18
Contractile parameters
Fdev (mN/mm
2) 23.7 ± 3.6 23.1 ± 1.1 0.91
+dF/dtmax (mN/mm
2/s) 298 ± 37 277 ± 21 0.70
TtPF (ms) 145 ± 16 139 ± 7 0.77
Relaxation parameters
-dF/dtmin (mN/mm
2/s) −204 ± 20 −130 ± 16 0.02*
RT50% (ms) 166 ± 9 209 ± 6 0.01*
Tau (ms) 74 ± 4 93 ± 7 0.03*
CSA - cross sectional area; Lmax- muscle length at maximal force development;
Fdev - developed force; +dF/dtmax - maximum rate of contraction; TtPF - time
to peak force; −dF/dtmin - minimum rate of relaxation; RT50% - 50% relaxation
time; Tau - time constant of relaxation. Data are mean ± SEM; * = p < 0.05 vs.
non-diabetic, unpaired t-test.









































Figure 1 Contraction and relaxation during force-length relationshi
relationship from 80 to 100% Lmax in isolated isometric contracting right at
and type 2 diabetic (DM, open circles, n = 6) patients. The contractile param
(+dF/dtmax, B) were not different between both groups. However, both rel
constant of relaxation (Tau, D) were impaired in muscles from type 2 diabe
early and late relaxation in human diabetic right atrial myocardium with pr
vs. 80% Lmax for both non-DM and DM group; Group effect: # = p < 0.05 vs. n
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SERCA2a and PLB were determined in the right atrial
samples (Figure 2). In line with the preserved contractile
function observed in DM muscles, the expression of the
SR Ca2+ release protein RyR2 was not different between
both groups of patients (0.85 ± 0.09 vs. 1.14 ± 0.19, non-
DM vs. DM, p = 0.14; Figure 2B). However surprisingly,
despite the impaired relaxation, the expression of SER-
CA2a, responsible for SR Ca2+ re-uptake was increased
in DM patients (0.75 ± 0.09 vs. 1.23 ± 0.15, non-DM vs.
DM, p = 0.007; Figure 2C). Moreover, the expression of
PLB, the endogenous inhibitor of SERCA2a, was de-
creased in the cardiac tissue of DM patients (2.21 ± 0.45
vs. 0.42 ± 0.11, non-DM vs. DM, p = 0.01; Figure 2D). Con-
sequently the SERCA2a:PLB ratio, which correlates with
SERCA2a activity, showed an increase in DM group (0.98 ±
0.31 vs. 3.92 ± 0.65, non-DM vs. DM, p = 0.0001; Figure 2E),
suggesting significantly enhanced SR Ca2+ re-uptake.% Lmax
% Lmax






































p in human right atrial cardiac muscles. Preserved force-length
rial cardiac muscles from non-diabetic (non-DM, closed circles, n = 8)
eters, developed force (Fdev, A) and maximum rate of contraction
axation parameters, minimum rate of relaxation (−dF/dtmin, C) and time
tic patients. Overall this indicates preserved contraction but impaired
eserved LV ejection fraction. Two-way ANOVA: length effect: * = p < 0.05















































































































Figure 2 Expression of calcium-handling proteins. A. Membranes containing human right atrial cardiac tissue samples from non-diabetic
(non-DM) and diabetic (DM) patients were probed for RyR2, SERCA2a, PLB, and GAPDH. RyR2 was detected above 250 kDa, SERCA2a between
100 kDa and 130 kDa, PLB below 10 kDa and for all samples GAPDH above 35 kDa as loading control. Western blot analysis showed similar protein
expression for B. RyR2, whereas C. SERCA2a expression was increased and D. the expression of PLB was more than five times lower in the
cardiac tissue of diabetic patients. E. Consequently the SERCA2a:PLB ratio showed a four times increase in the diabetic group compared to
non-diabetic group. Data are means ± SEM, obtained from four replica experiments using non-DM (n = 16) and DM (n = 8) patient samples,
except non-DM for RyR2 from n = 12; * = p < 0.05 vs. non-DM, unpaired t-test.
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stimulation
As impaired diastolic function limits cardiac perform-
ance during exercise [11], we also evaluated whether the
impaired relaxation observed in the diabetic right atrial
myocardium might be further compromised during a
physiological challenge. Therefore, the human right atrial
cardiac muscles were also exposed to β-adrenergic stimu-
lation using incrementing doses of dobutamine (10−7 to
10−5 M). As expected, this resulted in an increase in the
amplitude of contraction (Fdev, Figure 3A), speed of con-
traction (+dF/dtmax, Figure 3B), speed of early relaxation
(−dF/dtmin, Figure 3C) and of late relaxation (Tau,
Figure 3D) in muscles from non-DM patients. Strikingly,
the β-adrenergic stimulation-induced increase in contract-
ility (Fdev and + dF/dtmax, Figure 3A and B) and acceler-
ation of relaxation (−dF/dtmin and Tau, Figure 3C and D)
were absent in muscles from DM patients. Using western
blot analysis we assessed whether the impaired inotropic
and lusitropic β-adrenergic responsiveness in diabetic
myocardium was related to reduced β1-adrenoreceptor
content. However, as shown in Figure 3F the expression
levels of the β1-adrenoreceptor were not different between
cardiac tissue samples from the non-DM and DM patients
(2.3 ± 0.3 vs. 1.9 ± 0.2 non-DM vs. DM, p = 0.22).
Myocardial fibrosis
In addition to impaired relaxation, changes in myocardial
stiffness could also lead to diastolic dysfunction, thereforewe next assessed whether increased fibrosis exists in
the diabetic right atrial myocardium. Collagen depos-
ition was determined in cardiac tissue samples using
picro-sirius red, which selectively stains collagen red.
A 60% increase in collagen deposition was observed in
DM patients (4.9 ± 0.2% vs. 7.5 ± 0.5%, non-DM vs. DM,
p = 0.003; Figure 4), indicating increased myocardial
fibrosis in DM patients.
Discussion
Our findings show that in human right atrial myocardium
from type 2 diabetic patients, with CAD and preserved EF,
the contractile state is preserved, whereas relaxation is
impaired, despite an increase in SERCA2a:PLB expression
ratio. This is associated with an increased level of atrial
myocardial fibrosis. The increase in SERCA2a:PLB ratio
may suggest a compensatory mechanism in an attempt to
maintain diastolic function at rest despite impaired relax-
ation in the fibrotic diabetic atrial myocardium. We also
show for the first time that human right atrial cardiac
muscles from patients with type 2 diabetes and preserved
EF are unresponsive to β-adrenergic stimulation without a
change in expression level of the β1-adrenoreceptors, sug-
gesting impaired downstream β-adrenergic modulation.
Our study provides novel information on the underlying
pathology of diastolic dysfunction in the diabetic myocar-
dium, strengthening the knowledge base for the develop-





















































































































Figure 3 Myocardial function during β-adrenergic stimulation. In response to incrementing doses of β-adrenergic agonist dobutamine (10−7
to 10−5 M) right atrial cardiac muscles from non-diabetic patients (non-DM, closed circles, n = 8) showed an increase in amplitude of contraction
(Fdev, A), and speed of contraction (+dF/dtmax, B); and a faster speed of early relaxation (−dF/dtmin, C) and late relaxation (Tau, D). Strikingly, both
the increase in the contractile parameters (Fdev and + dF/dtmax) and the hastening of the relaxation parameters (−dF/dtmin and Tau) were absent
in the cardiac muscles from the diabetic patients (DM, open circles, n = 6). E. Western blotting was performed with human cardiac tissue samples
from non-diabetic (non-DM) and diabetic (DM) patients probed for β1–adrenoceptor (β1-AR) and β-actin. In representative blot β1–AR was detected
just below 50 kDa and β-actin above 37 kDa as loading control. F. Western blot analysis showed similar protein expression for β1–adrenoceptor. For all
functional parameters two-way ANOVA Bonferroni’s posthoc: dose effect, * = p < 0.05 and DM effect, # = p < 0.05). For protein analysis data obtained
from four replica experiments, non-DM (n = 10) and DM (n = 9) patients, unpaired t-test. Data are mean ± SEM.
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myocardium at rest
Our in vivo echocardiography data and our ex vivo cardiac
muscle data confirmed both preserved contractile function
with no development of structural cardiac hypertrophy in
diabetic patients with preserved EF. Echocardiography ofthe left ventricle also revealed a slower early filling time
(prolonged deceleration time) and higher filling pressures
during early filling (increased E/e’) with a tendency to
slower early and late filling velocities (E and A, respect-
ively), which in the isolated right atrial muscles were ac-































Figure 4 Collagen deposition. A. Representative images showing collagen density of picro-sirius red stained right atrial myocardial tissue samples
from non-diabetic (non-DM, n = 6) and diabetic (DM, n = 7) patients; yellow/brown staining represents myocardial fibers and red staining represents
collagen fibers. B. Calculated collagen deposition was increased in DM group compared to non-DM group; collagen deposition reported as % of
collagen in total tissue area/field from 21 fields/sample. Data are mean ± SEM; * = p < 0.05 vs. non-DM, unpaired t-test.
Lamberts et al. Cardiovascular Diabetology 2014, 13:72 Page 8 of 12
http://www.cardiab.com/content/13/1/72(decreased -dF/dtmin and prolonged Tau). Together these
data indicate reduced diastolic function due to impaired re-
laxation and increased myocardial stiffness of the heart in
the diabetic population with preserved EF. This is consist-
ent with previous echocardiography findings in type 1 and
type 2 diabetic patients [2,23] and with functional myocar-
dial studies in type 1 [24] and type 2 diabetic animal
models [25], however the myocardial diastolic dysfunction
observed in animal models was always accompanied by
systolic dysfunction. On the contrary, Reuter et al. have
reported no difference in the rate of relaxation or the con-
tractile function of right atrial cardiac muscles from type 2
diabetic patients undergoing CABG [26]. However, the
contractile and relaxation measurements reported in that
study were much lower in magnitude when compared to
values reported in other studies using human right atrial
cardiac muscles [27,28] and our study (Table 2). This may
be related to tissue degradation in their samples due to
prolonged loading with a fluorescence indicator, while our
experimental measurements were obtained within 90 mi-
nutes after dissection.
The heart has the ability to increase its cardiac effi-
ciency via intrinsic means, such as volume [29]. Several
studies reported that the Frank-Starling mechanism is
maintained in patients with reduced EF [28,30]. More
recently, patients with preserved EF showed a preserved
static (intrinsic to the heart) Frank-Starling mechanism
[31], whereas the beat-to-beat dynamic (including the
heart-arterial interaction) Frank-Starling mechanism
was impaired in these patients [32]. By increasing the
length of our isolated cardiac muscles we mimicked
the myocardial stretch and recorded a similar increase
in force development in both our non-DM and DM
groups. This indicates a preserved Frank-Starling mech-
anism in diabetic patients with preserved EF, and sup-
ports the concept that arterial stiffening might be
more important for the observed impaired dynamic
Frank-Starling mechanism during preserved EF than
myocardial stiffening [32].Impaired relaxation during physiological challenge
Although contractile function at rest was not altered by
diabetes, the relaxation of the right atrial diabetic mus-
cles was impaired over the entire range of myocardial
stretch, and both the inotropic and lusitropic responses
to β-adrenergic stimulation were completely absent in
cardiac muscles from DM patients. A reduced but still
responsive myocardium to β-adrenergic stimulation has
been observed in many diabetic animal models [33,34]
and has been related to reduced expression levels of
β1-adrenoreceptors [35]. Surprisingly, cardiac muscles
from our cohort of diabetic patients failed to respond
to the β-adrenergic stimulation, even at very high (10−5 M)
concentrations, which would indicate a lack of contractile
reserve even in these patients with normal resting con-
tractile function. In addition, our new data emphasizes
that caution should be taken with translating animal
data directly to the human situation. It would be easy
to attribute this to the use of β-adrenoceptor blocking
agents, however almost all patients, both the diabetic
and the non-diabetic, were on β-blocker treatment
(Table 1). Secondly, although the hemodynamic re-
sponses to dobutamine are reduced in diabetic patients
[36] they normally still do respond. Consequently the
non-responsiveness to β-adrenergic stimulation in the
isolated right atrial cardiac muscles in our study should
reside within the myocardium. Thirdly, although a reduced
expression of β1-adrenoreceptors has been reported in
myocardial tissue from diabetic patients undergoing CABG
in the absence of β-blockers [37], to the best of our know-
ledge expression of β1-adrenoreceptors has never been
reported in human myocardial tissue from diabetic patients
with preserved EF. Interestingly, we did not observe a
statistically significant reduction in β1-adrenoreceptors
expression levels (Figure 3F) in the cardiac tissue from
our diabetic cohort. Therefore, we suggest that the
reduced β-adrenergic inotropic and lusitropic responses
in the diabetic myocardium from patients with preserved
EF are related to alterations in downstream β-adrenergic
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ant downstream target of β-adrenergic signaling and we
observed a markedly reduced PLB protein expression in
the diabetic myocardium. Indirectly this implies there is
less PLB to be phosphorylated and therefore this could be
the reason for the reduced β-adrenergic inotropic and
lusitropic responses in the diabetic myocardium from
patients with preserved EF. Alternatively, Daniels et al. sug-
gested that reduced β-adrenergic responsiveness in diabetes
is related to metabolic changes leading to impaired energy
conversion, which becomes apparent during physiological
challenge [34]. Additionally, it was recently shown that
although exercise limitations were similar between patients
with reduced and preserved EF, significant differences
occurred in their exercise-induced changes in systolic and
diastolic properties, again reflecting their different under-
lying pathologies [38].
Underlying mechanism of impaired relaxation
The underlying mechanism of the impaired relaxation
may be related to impaired Ca2+ cycling within the car-
diomyocytes. In human diabetic myocardium from pa-
tients with reduced EF a decreased level of RyR2 mRNA
was observed [39]. In contrast, the human atrial myocar-
dium from diabetic patients with preserved EF in our
study showed no change in expression of the SR Ca2+
release channel RyR2, which is consistent with the pre-
served contractile function observed. Interestingly, in
human non-diabetic and type 2 diabetic patients with
preserved EF, it was reported that both SERCA2a and
PLB expression were similar [26], and recently mRNA of
SERCA was also shown to not be different between
diabetic and non-diabetic spontaneously hypertensive
rats [40], which is in contrast to our study showing an
increased SERCA2a protein expression and a decrease in
PLB protein expression. However, an altered mRNA
level does not always equate to altered protein expres-
sion. Moreover, our observed changes in SERCA2a and
PLB expression lead to an increase in the SERCA2a:PLB
ratio in myocardial tissue of DM patients. From our
data, which suggest accelerated SR Ca2+ uptake, it is
tempting to speculate that the changes in protein
density reflect a compensatory mechanism to attempt
to normalize the impaired relaxation at rest. This is
supported by the findings of Selby et al. [10] who sug-
gested that in myocardial muscles obtained from non-
diabetic patients with preserved EF, the impaired relaxation
is accompanied by a disproportionate increase in SR Ca2+
content due to an increase in SR Ca2+ uptake. Notably,
they found that increased SR Ca2+ content did not trans-
late into a stronger contraction [10]. In addition, our re-
sults are supported by studies using rodent diabetic models
that have reported an up-regulation of SERCA2a, a down-
regulation of PLB and an improved contractile functionfollowing insulin treatment [19,41]. These authors showed
that expression of SERCA2a mRNA in cardiomyocytes
is under control of insulin, associated with changes in
SR-Ca2+ uptake and phosphorylation of Akt, and inhibited
by phosphoinositide 3 (PI3)-kinase inhibitor wortmanin
[19]. This indicates that the underlying cellular mechanism
for upregulation of SERCA2a could be mediated by the
PI3-kinase-Akt-SERCA2a signaling cascade, suggesting
that subtle changes in Ca2+ regulation, which promote
diastolic dysfunction prior to overt systolic dysfunction,
may be common to early stages of type 2 diabetes involving
insulin resistance [19,42]. Moreover, it was shown recently
that elevated oxidative stress may induce oxidative modifi-
cations of SERCA2a that could contribute to abnormal
function in high-sucrose fed rats mimicking the metabolic
syndrome heart [43].
In the present study, DM patients had an increase in
hyperglycemic markers (glucose and HbA1c), despite all
being on hyperglycemic control medication (metformin
and insulin), and therefore changes in the expression of
calcium-handling proteins might still be due to altered
glycemic control. These changes in Ca2+ regulation may
over time increase the energy demands of the diabetic
myocardium and have important ramifications for
future diabetic myocardium remodeling, potentially
further impairing relaxation and eventually leading to
myocardial dysfunction. Therefore, the increased SER-
CA2A:PLB expression ratio may be compensatory and
beneficial for relaxation at resting conditions, but once
the myocardium is challenged, there is little reserve for
an increase in Ca2+ cycling leading to the lack of re-
sponse to β-adrenergic stimulation observed in our
study. Alternatively, in rodent models, experimental
diabetes changed the phosphorylation of the sarco-
meric protein troponin I [44,45] and also markedly
shifted the myosin heavy chain (MHC) from the fast
(V1) to the slow (V3) isoform [46,47], although the
later might be less important in humans as most MHC
already is predominantly in the slow isoform [48]. How-
ever, these studies indicate that myocardial relaxation can
also be affected by alterations in regulatory myofilament
proteins of the cardiac actomyosin system of which upon
the effects of diabetes in humans are unknown.
A well-known underlying cause of diastolic dysfunc-
tion is increased myocardial fibrosis. The extracellular
matrix remodeling plays an important role in cardiac fi-
brosis and the amount of extracellular collagen is caused
by an imbalance between synthesis and degradation of
collagen [49,50] and formation of advanced glycation
end-products [51]. Cardiac fibrosis leads to increased
myocardial stiffness, eventually resulting in both systolic
and diastolic dysfunction [6]. Increased fibrosis is com-
monly observed in diabetic animal models (see review
[50]), whereas reports in human cardiac tissue are
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position in the right atrium of diabetic patients is indica-
tive of increased fibrosis. Alternatively, increased diastolic
myocardial stiffness could result from an increased cardio-
myocyte stiffness, which relates to the elasticity of the
giant cytoskeletal protein titin and is determined by its
isoform expression [52] and/or posttranslational modifica-
tion [53,54]. Changes in isoform expression of titin have
been observed in type 1 diabetic animal models [47,55,56].
Recently in a metabolic animal model hyperphosphoryla-
tion of titin contributed importantly to underlying dia-
stolic dysfunction [54]. However the specific role of titin
regulating diastolic (dys) function, especially in type 2
diabetes in humans, is still not clear.
Limitations
Due to the use and access to human tissue, there are a
number of limitations to our study. CAD is known to be
a co-morbidity and a specific causal factor for the transi-
tion from diastolic to systolic failure [22]. As all our
patients had CAD for inclusion into the study, our data
were not compared to healthy human myocardium, so it
is unclear if our findings would translate to patients with
DM but without CAD. Non-transplanted donor heart
tissue is the closest available “non-diseased’ human myo-
cardial tissue, and our force values obtained in right
atrial cardiac muscles from non-DM patients with CAD
and preserved EF were similar to data from LV myocar-
dial tissue of non-transplanted donor hearts [28], al-
though caution should still be taken that the function of
the “non-diseased” hearts might still be affected by the
cause of death (such as accident trauma), the use of
cardioplegic solutions and the variable elapsed time be-
tween removal of the heart and the dissection of cardiac
muscles. Nevertheless, diabetic patients with CAD are
an extensive cohort [57] and are known to have double
the risk of progressing to HF compared to non-diabetic
CAD patients [58], and therefore our findings provide
important novel and relevant knowledge to a clinically
large and important patient group.
Another limitation is that differences in the ultrastruc-
ture and Ca2+ dynamics between the atria and ventricular
myocardium exists [59] , which need to be carefully con-
sidered when translating right atrial findings to the left
ventricular myocardium or the whole heart. For instance
it has been shown that atrial tissue expresses relatively
more SERCA2a and less PLB compared to ventricular
tissue [60]. On the other hand, cardiac muscles obtained
from right atrial appendages have been extensively used to
study the function of human myocardium [9,26-28].
Conclusions
In patients with CAD and preserved EF, the existence of
type 2 diabetes resulted in impaired relaxation andincreased fibrosis of the right atrium, with preserved
myocardial contractile function. Our novel finding of
increased expression of SERCA2a:PLB ratio suggests a
compensatory mechanism to enhance relaxation and
maintain the diastolic function at rest of the fibrotic
diabetic atrial myocardium. We also demonstrate for
the first time that human right atrial cardiac muscles
from type 2 diabetic patients with preserved EF are unre-
sponsive to β-adrenergic stimulation despite no change in
expression of the β1-adrenoreceptor expression levels,
suggesting impaired downstream β-adrenergic modula-
tion and lack of contractile reserve. Our study provides
novel knowledge on the underlying pathology of dia-
stolic dysfunction in the diabetic myocardium.
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